ChemFeeds Site Navigation:
Journal Selection:
Search:

1) BAI1 and Nestin in Breast Cancer Brain Metastases (Molecular Cancer Therapeutics) Wednesday January 14th 2015


2) Kinase Inhibitor Responses in Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


3) JAGGED2 Promotes Pancreatic Cancer Cell Migration (Molecular Cancer Therapeutics) Wednesday January 14th 2015


4) MET Amplification in Human and Murine Prostate Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


5) ANRIL Promotes Proliferation in NSCLC (Molecular Cancer Therapeutics) Wednesday January 14th 2015


6) Lack of NPP7 Enhances Colonic Tumorigenesis (Molecular Cancer Therapeutics) Wednesday January 14th 2015


7) LIM Kinases in Prostate Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


8) Human Nucleoside Transporter Inhibition by Kinase Inhibitors (Molecular Cancer Therapeutics) Wednesday January 14th 2015


9) {Delta}NP63{alpha}-Dependent CSC Behavior Is Regulated through CXCR4 (Molecular Cancer Therapeutics) Wednesday January 14th 2015


10) Inhibition of Neuroblastoma Development by Targeting Midkine (Molecular Cancer Therapeutics) Wednesday January 14th 2015


11) Arsenic Trioxide Directly Inhibits AMPK (Molecular Cancer Therapeutics) Wednesday January 14th 2015


12) Resistance to Cabazitaxel (Molecular Cancer Therapeutics) Wednesday January 14th 2015


13) SRT1720 Induces Lysosomal-Dependent Cell Death (Molecular Cancer Therapeutics) Wednesday January 14th 2015


14) Targeting CDKN1A/TP53 in Bladder Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


15) Preclinical Pharmacokinetics and Safety of Metuzumab (Molecular Cancer Therapeutics) Wednesday January 14th 2015


16) Diffusion of Bicyclic Peptides into Tumors (Molecular Cancer Therapeutics) Wednesday January 14th 2015


17) NIR-PIT for Disseminated Peritoneal Ovarian Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


18) Peptide-mAb Con{#x0237}ugate Crosses the Blood-Brain Barrier (Molecular Cancer Therapeutics) Wednesday January 14th 2015


19) iRGD Inhibits Metastasis and Repels Tumor Cells (Molecular Cancer Therapeutics) Wednesday January 14th 2015


20) Novel TMZ Analogues Overcome GBM Resistance (Molecular Cancer Therapeutics) Wednesday January 14th 2015


21) Combination of Axitinib and Crizotinib in Human Renal Cell Carcinoma (Molecular Cancer Therapeutics) Wednesday January 14th 2015


22) PP2A Inhibition Sensitizes Ovarian Cancer Cells to Cisplatin (Molecular Cancer Therapeutics) Wednesday January 14th 2015


23) YM155 Induces Apoptosis via DR5 in Pancreatic Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


24) Radioprotection of Brain Structure and Function by Porphyrin (Molecular Cancer Therapeutics) Wednesday January 14th 2015


25) Preclinical Evaluation of VT-464 in Prostate Cancer Models (Molecular Cancer Therapeutics) Wednesday January 14th 2015


26) AZD8186 Inhibits PI3K{beta}-Dependent Tumor Growth (Molecular Cancer Therapeutics) Wednesday January 14th 2015


27) MEK and PI3K Inhibition in Pancreatic Cancer (Molecular Cancer Therapeutics) Wednesday January 14th 2015


28) Preclinical Profile of Choline Kinase Alpha Inhibitors (Molecular Cancer Therapeutics) Wednesday January 14th 2015


29) Darinaparsin Kills Prostate Cancer Cells by Inhibiting Shh Signaling (Molecular Cancer Therapeutics) Wednesday January 14th 2015


30) Preclinical Characterization of HSP90{alpha}/{beta} Inhibitor TAS-116 (Molecular Cancer Therapeutics) Wednesday January 14th 2015


31) Repurposing Mebendazole as a Hedgehog Inhibitor (Molecular Cancer Therapeutics) Wednesday January 14th 2015


32) Acknowledgment to Reviewers (Molecular Cancer Therapeutics) Thursday December 4th 2014


33) Targeted Drug Discovery with TCGA, CMap, and CCLE (Molecular Cancer Therapeutics) Thursday December 4th 2014


34) Mouse Model of Human Lymphoma Therapy Heterogeneity (Molecular Cancer Therapeutics) Thursday December 4th 2014


35) BRAFV600E Blood Test (Molecular Cancer Therapeutics) Thursday December 4th 2014


36) Combinatorial Targeting of Notch1 and Ras/MAPK in Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


37) miR-185 Is a Potential Target for TNBC Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


38) Outcomes of Phase I Trials in Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


39) Role of miR24 in Nasopharyngeal Carcinoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


40) miR141-CXCL1-CXCR2 Recruits Tregs in MPE (Molecular Cancer Therapeutics) Thursday December 4th 2014


41) miR200c Induces MDR and Metastasis (Molecular Cancer Therapeutics) Thursday December 4th 2014


42) Akt-Activated Endothelium and Bevacizumab in Ovarian Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


43) Doxycycline and Hepatocellular Carcinoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


44) MEK1 Gene Mutation and Gastric Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


45) PTENP1 as ceRNA in ccRCC (Molecular Cancer Therapeutics) Thursday December 4th 2014


46) ADAM9 in Gastric Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


47) Cellular Role of A687V EZH2 in ALL (Molecular Cancer Therapeutics) Thursday December 4th 2014


48) RRAD Induces Temozolomide Resistance of Glioblastoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


49) JAK1/STAT3 as a Therapeutic Target in Ovarian Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


50) Rapamycin Augments Antiglioma Immunotherapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


51) CBS9106-Induced CRM1 Degradation Requires CRL Activity (Molecular Cancer Therapeutics) Thursday December 4th 2014


52) GEP Antibody and Chemosensitization (Molecular Cancer Therapeutics) Thursday December 4th 2014


53) ADC Targeting LIV-1 for Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


54) Tivantinib Overcomes Drug Resistance by ABC Transporter (Molecular Cancer Therapeutics) Thursday December 4th 2014


55) Selective Radioprotection of Normal Tissues (Molecular Cancer Therapeutics) Thursday December 4th 2014


56) Cannabinoid Activity in an Orthotopic Murine Glioma Model (Molecular Cancer Therapeutics) Thursday December 4th 2014


57) C. vasculum Compounds Possess Antitumor Potential (Molecular Cancer Therapeutics) Thursday December 4th 2014


58) Ashwagandha Inhibits Metastasis and Angiogenesis (Molecular Cancer Therapeutics) Thursday December 4th 2014


59) Novel Pan-ERBB Inhibitor for Treating Glioblastoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


60) Alectinib Is a Potent Inhibitor of RET (Molecular Cancer Therapeutics) Thursday December 4th 2014


61) Cathepsin K Inhibitor for Metastatic Bone Disease (Molecular Cancer Therapeutics) Thursday December 4th 2014


62) Carfilzomib and Ricolinostat in NHL Cells (Molecular Cancer Therapeutics) Thursday December 4th 2014


63) In Vivo KRAS Silencing with siRNA (Molecular Cancer Therapeutics) Thursday December 4th 2014


64) Antitumor by Phage Protein-Targeting Micellar Paclitaxel (Molecular Cancer Therapeutics) Thursday December 4th 2014


65) PET Imaging of {beta}G Activity for Prodrug Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


66) Combination Therapy for KIT-Mutant Mast Cells (Molecular Cancer Therapeutics) Thursday December 4th 2014


67) NT157 Suppresses IRS1/2 and Augments Prostate Cancer Therapeutic Response (Molecular Cancer Therapeutics) Thursday December 4th 2014


68) Targeting PCNA for Cancer Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


69) Inhibition of MCT1 Potentiates Radiotherapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


70) AT13387 Delays and Overcomes Resistance in Melanoma Models (Molecular Cancer Therapeutics) Thursday December 4th 2014


71) Vorinostat Decreases CD30 and Brentuximab Vedotin Efficacy (Molecular Cancer Therapeutics) Thursday December 4th 2014


72) BRAF Mutations and Immunity in Melanoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


73) Correction: The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells (Molecular Cancer Therapeutics) Tuesday November 4th 2014


74) PDT with a Glucose-Conjugated Chlorin for GIST--Response (Molecular Cancer Therapeutics) Tuesday November 4th 2014


75) PDT with a Glucose-Conjugated Chlorin for GIST--Letter (Molecular Cancer Therapeutics) Tuesday November 4th 2014


76) Stromal Targets of Multikinase Inhibitors (Molecular Cancer Therapeutics) Tuesday November 4th 2014


77) PI3K Pathway Inhibition and Resistance Mechanisms in HNSCC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


78) Camptothecin Tissue Penetration and Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


79) The SNAI2:miR145 Axis and Chemotherapeutic Response (Molecular Cancer Therapeutics) Tuesday November 4th 2014


80) The Effect of Irradiation on Multidrug Resistance (Molecular Cancer Therapeutics) Tuesday November 4th 2014


81) Fn14-Targeted Therapeutics (Molecular Cancer Therapeutics) Tuesday November 4th 2014


82) Triple Fusion Protein Targeting Angiogenesis (Molecular Cancer Therapeutics) Tuesday November 4th 2014


83) MEDI-573, Alone or with mTOR Inhibitors, Targets Sarcoma IGF (Molecular Cancer Therapeutics) Tuesday November 4th 2014


84) RG7787 in Gastric and Triple-Negative Breast Cancers (Molecular Cancer Therapeutics) Tuesday November 4th 2014


85) An Antibody-Cytokine-Drug Con{#x0237}ugate with Antitumor Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


86) Preclinically Efficacious Antimesothelin-MMAE Con{#x0237}ugate (Molecular Cancer Therapeutics) Tuesday November 4th 2014


87) Preclinical Profile of SYD983/SYD985 (Molecular Cancer Therapeutics) Tuesday November 4th 2014


88) Anti-MET ImmunoPET (Molecular Cancer Therapeutics) Tuesday November 4th 2014


89) Optical Imaging of Prostate Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


90) Inhibition of PSCs by Bisphosphonates in PDAC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


91) Targeting MLL5{beta} for Cervical Cancer Therapy (Molecular Cancer Therapeutics) Tuesday November 4th 2014


92) Monensin Enhances Erlotinib Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


93) Efficacy of CH5183284 against Tumors with FGFR Aberrations (Molecular Cancer Therapeutics) Tuesday November 4th 2014


94) Small Molecule Pol I Inhibitors (Molecular Cancer Therapeutics) Tuesday November 4th 2014


95) Pazopanib for FGFR2 Amplification in Gastric Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


96) SEMs for the Treatment of Tamoxifen-Resistant Breast Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


97) Targeting Hypoxia and HR Repair Defects in TNBC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


98) Targeting mTOR Kinase/IGF1R Feedback in Multiple Myeloma (Molecular Cancer Therapeutics) Tuesday November 4th 2014


View: prev | next

#RealTimeChem:

Announcements:

Chem News Feed:

Epoxides – The Outlier Of The Ether Family

NEBULA IN A FLASK University of Rhode Island chemistry grad...

India's GVK Accused of Systematic Fraud

Mobile Test Could Detect Viral DNA Without PCR

Tolerant Chemistry: Be Glad of It

What do you do when your interviewer is wrong?

So that's an interesting quote about IP stuff in China: "Even if they are published, they are difficult to duplicate.”

New Pleasures for the Nose

This week's C&EN

Researchers With Ties To Chemistry Among National Academy Of Sciences Awardees

Why this popular chemistry experiment is a blast

Are New Biopharmas Being Formed Quickly Enough?

Angewandte Chemie 5/2015: The Power of Chemistry

Orangutans take the low road

Skull fractures aren’t what they used to be


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()